Moderna Inc stated on Monday its COVID-19 vaccine generated a robust immune response and was typically well-tolerated in kids aged six to 11 years, and the corporate plans to submit the info to regulators quickly.
Moderna stated its two-dose vaccine generated virus-neutralizing antibodies in kids and security was similar to what was beforehand seen in scientific trials of adolescents and adults.
A panel of FDA advisers will vote on Tuesday whether or not to authorize rival Pfizer and BioNTech’s COVID-19 vaccine to be used in kids aged 5 to 11 years.
The Moderna COVID-19 vaccine has been licensed for adults over the age of 18 years, and not too long ago gained clearance for a 3rd dose in some Individuals.
Learn extra:
U.S. CDC approves Moderna, J&J COVID-19 vaccine boosters, together with mixing of photographs
Nonetheless, the U.S. Meals and Drug Administration is but to authorize the vaccine to be used in adolescents aged 12 by 17. Sweden has paused the usage of the Moderna vaccine for youthful age teams after studies of instances of coronary heart irritation in younger adults.
Moderna stated majority of the unwanted effects within the trial, which had 4,753 contributors, had been gentle or reasonable in severity, with fatigue, headache, fever and injection website ache the commonest.
The vaccines used within the trial had been 50 microgram doses, half the power used within the major vaccine sequence for adults. The 50 microgram dose can also be licensed to be used as a booster shot.
View hyperlink »
